| In recent years WHO has initiated to develop child inoculate against many kinds of disease's vaccines,this new vaccine is"more and more of the price of"vaccine from the existing production Variety and the vaccine inoculation needle contained in the vaccine antigen, and the characteristics of such considerations that developed hepatitis A freeze-dried - mumps vaccine is feasible, and the joint development of freeze-dried vaccines, freeze-dried protection of the ratio of research is the important and indispensable aspect of the role of a connecting link. After several years of research results show that: hepatitis A freeze-dried - mumps vaccine pre-clinical studies of viable animal test results show that the immunogenicity of good products, safe, effective and consistent with the Joint Vaccine development strategy. Preparation combined vaccine first problem is to solve the Joint whether the virus will have to reduce interference immunity immune response, as well as joint cross-reaction between the vaccine components to increase toxicity. Literature indicates that hepatitis A vaccine and mumps vaccine inoculation at the same time does not interfere with the immune response of mumps vaccine and do not affect the immune effect of hepatitis A vaccine. At the same time has not increased after vaccination reactions and abnormal reaction that the mumps vaccine and live attenuated hepatitis A vaccine can be vaccinated. Freeze-drying results of the study of hepatitis A - a joint mumps vaccine research raise the basis for.This paper mainly to the following aspects:(1) the success of a hepatitis A vaccine stock solution with the ratio of mumps vaccine Solution;(2) the success of a hepatitis A freeze-dried - mumps vaccine protection of the ratio of freeze-dried; (3) the freeze-dried hepatitis A - mumps vaccine joint monkey safety and immunogenicity of the inspection, major neurological toxicity, safety and immunogenicity of the inspection work, demonstrating the feasibility of the pilot programme. |
PDF Full Text Request